Tools
Stock profile

PFIZER INC (PFE)

PFE · Latest close $28.06 as of Nov 18, 2026 · 13F data as of Jun 30, 2026 (2026 Q2)
Latest close
$28.06
As of Nov 18, 2026
Tracked funds holding
16 of 149
2026 Q2 13F filings
Opened / added
1 / 6
vs previous quarter
Trimmed / exited
9
vs previous quarter

PFIZER INC (PFE) is held by 16 of 149 tracked super-investor funds (144 filed in Q2) in 2026 Q2 13F filings, with 1 fund opening new positions, 6 funds adding, and 9 funds trimming or exiting versus the previous quarter. 0 members of Congress reported 0 purchases vs 1 sale. Latest close $28.06 as of Nov 18, 2026.

Data as of Nov 18, 2026 (prices) · 2026 Q2 13F filings (quarter ended Jun 30, 2026) · Latest Form 4: none in the last 90 days · Congress to Nov 16, 2026.

Funds
2026 Q2 13F
Congress
0 buys vs 1 sale
Fundamentals
Revenue · FY2025
Red flags
none flagged
Short interest
as of Oct 15, 2026
Holdings · Charts · All institutions · Fundamentals · Short interest · Fails to deliver · Insider trading · 5% holders · Planned sales · Politician trading · Committee jurisdiction · Government relations · Screens & lenses · Signal record · Related stocks · Recent 8-K

Funds holding this

Hillman Capital Management · Sound Shore · Torray Investment Partners LLC — 16 tracked funds hold PFE. See all holders.

Insider and Congress activity

0 members of Congress reported buying (0 purchases vs 1 sale). Politician trading

Often held alongside

Arcos Dorados Holdings Inc. (ARCO) · REGIONS FINANCIAL CORP (RF) · AMGEN INC (AMGN) · BP PLC (BP) · ALLSTATE CORP (ALL) — stocks the same funds also hold. See all related stocks.

Super-investor holdings · 2026 Q2

FundPortfolio weightSharesChange vs prev. quarter
Hillman Capital Management3.04%174,610TRIMMED (-7.1%) Q3 filed Nov 16
Sound Shore2.83%3,820,117ADDED (+33.1%) Q3 filed Nov 6
Torray Investment Partners LLC2.79%859,418ADDED (+10.7%) Q3 filed Oct 30
Kahn Brothers Group1.77%464,001TRIMMED (-4.3%) Q3 filed Nov 16
Fairfax Financial Holdings0.95%1,043,900ADDED (+5.3%) Q3 filed Nov 16
Deerfield Management0.76%3,040,000HELD Q3 filed Nov 16
Causeway Capital Management0.50%1,916,801ADDED (+0.1%) Q3 filed Nov 13
Thornburg Investment Management0.45%1,970,004TRIMMED (-12.1%) Q3 filed Nov 13
Pzena Investment Management0.42%5,958,922ADDED (+0.6%) Q3 filed Oct 30
Fairholme Capital0.37%231,000NEW Q3 filed Nov 16

Source: SEC Form 13F filings, quarter ended Jun 30, 2026. Change labels compare each fund’s 2026 Q2 filing with its previous filing. Fund counts aggregate every share class mapped to this ticker.

Price change since quarter-end: +19.2% from the close on the first trading day after the quarter ended (Jul 1, 2026) to the latest close (Nov 17, 2026). 13F does not report purchase prices — this is the price change since the quarter-end close, not a gain on any fund’s actual purchase.

Filing season: the Q3 2026 13F tracker follows every tracked fund’s filing for the quarter ended Sep 30, 2026, with its biggest buys and sells.

Charts

30.7921.222024-11-192026-11-18

Closing prices (unadjusted for dividends), last 2 years — 501 trading days to Nov 18, 2026. Dashed lines mark 13F filing deadlines. Source: Yahoo Finance daily bars.

252016Q3: 22 funds2016Q4: 25 funds2017Q1: 24 funds2017Q2: 22 funds2017Q3: 21 funds2017Q4: 22 funds2018Q1: 20 funds2018Q2: 21 funds2018Q3: 22 funds2018Q4: 20 funds2019Q1: 16 funds2019Q2: 16 funds2019Q4: 16 funds2020Q1: 17 funds2020Q3: 19 funds2020Q4: 19 funds2021Q2: 16 funds2021Q3: 17 funds2021Q4: 18 funds2024Q2: 17 funds2024Q3: 16 funds2026Q1: 17 funds2016Q32026Q1

Tracked funds holding this stock, by quarter (2016Q3–2026Q1, 22 quarters). Source: quarterly BEST lists from 13F filings — tracked funds only, not all filers. A stock appears here only if it ever made a quarterly BEST list.

All institutions · Form 13F

Institutions holding2,832 of 8,857 filers
Long-only filers among them2,823
Change vs 2026 Q1-88 net · 1,835 entered · 1,923 exited
Shares reported, all filers3,778,604,587
Reported value, all filers$92.8B

Source: SEC Form 13F data sets — every filer's latest report for the quarter ended Jun 30, 2026, not just the tracked funds above; changes compare with the quarter ended Mar 31, 2026. Share counts and values are summed as reported in the filings (a small number of filers report values in thousands of dollars, so value totals are as-filed sums).

Company fundamentals

ExchangeNYSE
IndustryPharmaceutical Preparations (SIC 2834)
Revenue · FY2025$62.6B
Net income · FY2025$7.8B
Total assets · FY2025$208.2B
Shares outstanding5,699,673,589
Market cap (at latest close)$159.9B

Source: SEC EDGAR company filings (submissions and company facts), collected Oct 30, 2026. Shares outstanding as reported Jul 29, 2026.

Short interest

Shares short · Oct 15, 2026137,816,093
Share of shares outstanding2.42%
Days to cover4.47

Shares short at recent settlements — Jul 31, 2026: 161.5M · Aug 14, 2026: 149.3M · Aug 31, 2026: 151.5M · Sep 15, 2026: 155.2M · Sep 30, 2026: 150.2M · Oct 15, 2026: 137.8M.

Source: FINRA Equity Short Interest (biweekly settlement data). Shares outstanding from SEC filings as of Jul 29, 2026.

Fails to deliver

Shares failed to deliver · Oct 14, 20260
Share of shares outstanding0.00%
Fails as a share of short interest · Oct 15, 20260.0%

Fails to deliver at recent settlements — Jul 31, 2026: 0 · Aug 14, 2026: 0 · Aug 31, 2026: 25K · Sep 15, 2026: 0 · Sep 30, 2026: 0 · Oct 14, 2026: 0.

Source: SEC Fails-to-Deliver data (semi-monthly files, published about two weeks after each settlement date). Each figure is the balance of shares not yet delivered on that date; a stock absent from that date’s file counts as zero. See our research on whether fails to deliver predict returns. Shares outstanding from SEC filings as of Jul 29, 2026.

Insider trading · Form 4

Data unavailable — no Form 4 transactions for this ticker were parsed in the last 90 days.

Planned sales · Form 144

FiledSellerRoleShares to sellMarket valueApprox. sale dateSource
May 23, 2025Dolsten MikaelFormer Officer59,781$1.4MMay 23, 2025SEC filing
May 5, 2025Dolsten MikaelFormer Officer55,000$1.3MMay 5, 2025SEC filing
Sep 13, 2023Pao WilliamFormer Chief Development Officer; EVP54,379$1.9MSep 13, 2023SEC filing

A Form 144 notice is a planned sale, not a completed sale. Most recent first. Source: SEC Form 144 filings, 63,013 notices from Apr 13, 2023 to Oct 9, 2026.

5% holders · Schedule 13D/G

FiledFilerFormShares% ownedEvent dateSource
May 1, 2026Vanguard Capital ManagementSC 13G427,444,8727.5%Mar 31, 2026SEC filing
Mar 27, 2026The Vanguard GroupSC 13G/A00.0%Mar 13, 2026SEC filing

One filing is one row; a filing may list several reporters and the first is shown. Figures are as filed, including amendments that report zero shares after a transfer. Source: SEC Schedule 13D/G filings, 57,443 filings parsed to Oct 2, 2026.

Politician trading · U.S. Congress

0 members of Congress reported buying (0 purchases vs 1 sale).

Source: U.S. House Clerk and U.S. Senate eFD STOCK Act periodic transaction reports, as of Nov 16, 2026. Reported amounts are ranges, and reports can arrive up to 45 days after the trade.

Recent activity by member

MemberChamberPartyBuysSellsLatestAmount range
Tuberville, TommySenateR01Jun 8, 2026$15,001 - 50,000

Member-level activity in the current window, most recent first (House data to Nov 16, 2026, Senate to Oct 1, 2026). House reports arrive as PDFs without transaction-level rows in the current corpus, so this table shows per-member totals, not individual trades; the member page lists the underlying filings. Senate rows link the same way — the member page carries the eFD filing links.

Committee jurisdiction

Industry: Pharmaceutical Preparations (SIC 2834). Standing committees with jurisdiction over this industry: Senate Committee on Health, Education, Labor, and Pensions, House Committee on Energy and Commerce.

Member who traded this stockSits on
Tuberville, TommySenate Committee on Health, Education, Labor, and Pensions

Assignments are the current (119th Congress) rosters. A trade made in an earlier Congress may have been made under a different assignment. Jurisdiction is by industry (SEC SIC code), not by anything the company said or did. Same rule as our committee-jurisdiction study.

Government relations

Lobbying: 1,192 Lobbying Disclosure Act filings named this company as client, 1999–2026; most common issues: Health Issues (626), Trade (domestic/foreign) (453), Taxation/Internal Revenue Code (425).

Federal contracts: $31.9B in obligated amounts, fiscal years 2021–2026.

Fiscal yearObligated amount
FY2021$13.3B
FY2022$16.7B
FY2023$1.9B
FY2024$-28.5M
FY2025$1.4M
FY2026$-127.7K

Largest awards collected

Award IDAgencyAmountStart
W58P0522C0001Department of Defense$12.5BNov 17, 2021
W15QKN21C0012Department of Defense$11.1BDec 22, 2020
W58P0521C0002Agency for International Development$4.2BJul 30, 2021
W58P0522C0016Department of Defense$4.0BJun 29, 2022
HHSD200201458152CDepartment of Health and Human Services$1.0BApr 1, 2014

Lobbying filings are matched by company core name; a filing can match more than one ticker. Contract amounts are obligated amounts (money committed, not money spent), matched by recipient name — contracts under a subsidiary’s name can be missed. Sources: Senate Lobbying Disclosure Act filings; USAspending.gov. See Methodology.

Screens & lenses

Insiders

· Opportunistic Buys (Non-Routine) — Last 90 days: 2 or more insiders with no routine buying pattern bought on the open market

Financial Screens

· Dividend Growth — Dividends raised for more than 10 years

· Cash Flow (FCF) — Positive free cash flow in each of the last 3 years, with an FCF yield of at least 5%

· Earnings Quality (Cash Conversion) — Profits that actually come back as cash

· Shareholder Yield — Cash returned through dividends and buybacks

Chart Signals

· Monthly Uptrend — Price above its 12-month moving average

Key figures

· Dividend Growth — Dividend per share: 1.72 · Dividend yield: 5.7% · Straight dividend years: 16 · 10-yr dividend growth: 41.0%

· Cash Flow (FCF) — Latest FCF: $9.1B · FCF yield: 5.3% · Positive FCF years: 3

· Earnings Quality (Cash Conversion) — Cash conversion (3-yr avg): 2.40 · Operating cash flow: $11.7B · Net income: $7.8B

· Shareholder Yield — Shareholder yield: 5.7% · of which dividends: 5.7% · of which buybacks: 0.0%

· Opportunistic Buys (Non-Routine) — Opportunistic buyers: 3 · Buy txns: 3 · Buy value: $3.0M · Latest buy: Aug 12, 2026

Financial screens are computed from SEC company financial statements; red-flag models are screens, not verdicts — see Methodology.

Signal record

· Super-investor 13F BEST — appeared in 22 of the last 40 quarterly lists; latest 2026 Q1, ranked #49 of 50.

· Politician BEST — appeared in 9 of the last 20 quarterly lists; latest 2025 Q2, ranked #40 of 50.

13F signal (2021 Q3 – 2026 Q1)EventsWin rateAvg returnSPYExcess
Heavy accumulation — 3+ tracked funds increased together966.7%+0.2%+0.4%-0.2%
Share count tripled (3x)1100.0%+1.5%+3.7%-2.2%

Measured from SEC 13F filings: entry at the close on the first trading day after each quarter’s filing deadline, exit one quarter later on the same rule, dividend-adjusted closes. Past records do not guarantee future results — see Track Record and Methodology.

Also held by the tracked funds that hold PFE — ranked by lift, the co-holding pattern described in Methodology: Arcos Dorados Holdings Inc. (ARCO) · REGIONS FINANCIAL CORP (RF) · AMGEN INC (AMGN) · BP PLC (BP) · ALLSTATE CORP (ALL) · CAMPBELL'S Co (CPB) · ING GROEP NV (ING) · TARGET CORP (TGT).

Filings audit: every filing lens on PFIZER INC (PFE), scored — GetCoattail Research.

Recent 8-K filings

FiledItemsSource
Nov 3, 20265.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers · 9.01 Financial Statements and ExhibitsSEC filing
Nov 3, 20262.02 Results of Operations and Financial Condition · 9.01 Financial Statements and ExhibitsSEC filing
Aug 4, 20262.02 Results of Operations and Financial Condition · 9.01 Financial Statements and ExhibitsSEC filing

Source: SEC EDGAR Form 8-K filings, latest first. Amendments (Form 8-K/A) are labeled as such. Item labels are the SEC's item titles; a filing can carry several items. Item 5.02 covers both departures and appointments, which this index does not distinguish.

Related

Arcos Dorados Holdings Inc. (ARCO) · Filings audit: every filing lens on PFIZER INC (PFE), scored · Practice timing on PFE

One email a week: the week’s new filings and research. Subscribe free

← PEPG  ·  PFG →

Open the interactive tool →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.